Baidu
map

Chest:慢性阻塞性肺病患者门诊戒烟的影响因素分析

2016-10-02 xing.T MedSci原创

研究表明青年和社会经济弱势的患者实现及时戒烟有更多的困难。一个新的发现是,病情温和的COPD的患者不太可能主动戒烟。因此,专注于这些亚组的干预性研究以确保戒烟成功,可以阻止疾病的进展。

众所周知,戒烟对慢性阻塞性肺疾病(COPD)进展会产生有益影响。尽管如此,许多慢性阻塞性肺病的患者仍在吸烟。近日,在《Chest》杂志上发表了一篇旨在分析COPD门诊患者戒烟影响因素的文章。

该研究是一个以全国性医院为基础的前瞻性随访研究,研究者分析了戒烟的临床和社会人口统计学因素,纳入了从2008年至2012年在门诊就诊的3233例COPD吸烟者。使用多变量Cox回归,研究者计算了患者戒烟的危险比。

研究者发现,在患者第一次门诊之后的1年和5年内,患者戒烟的概率分别为19%和45%。在调整混合因素后,研究者分析发现如果患者较为年轻,不太可能主动戒烟。此外,与年龄70岁以上的患者相比,年龄在50岁至69岁之间的患者COPD危险比为0.84(95%可信区间为0.71-0.99)、年龄在30至49岁之间患者COPD的危险比为0.53(95%可信区间为0.37-0.76)。那些年龄在70岁以上的COPD患者具有收入较低(危险比为0.79;95%可信区间为0.67-0.94)、孤独(危险比为0.75;95%可信区间为0.64-0.88)、失业(危险比为0.70;95%可信区间为0.54-0.90)等特征。在全球倡议A中的COPD的危险比为0.67(95%可信区间为0.53-0.84),在COPD的全球倡议B中,COPD的危险比为0.61(95%可信区间为0.47-0.80)。另外,年龄在70岁以上的COPD患者容易出现呼吸困难评分<4(危险比为0.80,95%可信区间为0.68-0.95)的情况,但没有在门诊治疗急性发作的病史(危险比为0.80;95%可信区间为0.68-0.93)。

研究表明青年和社会经济弱势的患者实现及时戒烟有更多的困难。一个新的发现是,病情温和的COPD的患者不太可能主动戒烟。因此,专注于这些亚组的干预性研究以确保戒烟成功,可以阻止疾病的进展。

原始出处:

Sandra S. Tøttenborg. et al. Determinants of Smoking Cessation in Patients With COPD Treated in the Outpatient Setting. Chest. 2016;150(3):572-596.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1929257, encodeId=730f192925e23, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jul 04 18:15:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050564, encodeId=bbcd2050564d2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 08 18:15:00 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671846, encodeId=02fd16e18467a, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri Feb 24 00:15:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696685, encodeId=280916966856c, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jun 01 22:15:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141127, encodeId=bce514112ebb, content=戒烟戒烟戒烟, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5Rzba0miciaDqB9IKh3iabPTt0b9S9puPOeouK5FKbP79ycicRtfibS0QUQzscofhYdIIBqEjojYTKIlnS3/0, createdBy=0f9c1961271, createdName=youyimu, createdTime=Thu Oct 06 17:10:06 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465528, encodeId=9f19146552821, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Oct 04 10:15:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139800, encodeId=f04c139800a7, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced11947358, createdName=猪猪霞, createdTime=Tue Oct 04 09:12:09 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2017-07-04 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1929257, encodeId=730f192925e23, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jul 04 18:15:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050564, encodeId=bbcd2050564d2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 08 18:15:00 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671846, encodeId=02fd16e18467a, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri Feb 24 00:15:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696685, encodeId=280916966856c, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jun 01 22:15:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141127, encodeId=bce514112ebb, content=戒烟戒烟戒烟, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5Rzba0miciaDqB9IKh3iabPTt0b9S9puPOeouK5FKbP79ycicRtfibS0QUQzscofhYdIIBqEjojYTKIlnS3/0, createdBy=0f9c1961271, createdName=youyimu, createdTime=Thu Oct 06 17:10:06 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465528, encodeId=9f19146552821, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Oct 04 10:15:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139800, encodeId=f04c139800a7, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced11947358, createdName=猪猪霞, createdTime=Tue Oct 04 09:12:09 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1929257, encodeId=730f192925e23, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jul 04 18:15:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050564, encodeId=bbcd2050564d2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 08 18:15:00 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671846, encodeId=02fd16e18467a, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri Feb 24 00:15:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696685, encodeId=280916966856c, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jun 01 22:15:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141127, encodeId=bce514112ebb, content=戒烟戒烟戒烟, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5Rzba0miciaDqB9IKh3iabPTt0b9S9puPOeouK5FKbP79ycicRtfibS0QUQzscofhYdIIBqEjojYTKIlnS3/0, createdBy=0f9c1961271, createdName=youyimu, createdTime=Thu Oct 06 17:10:06 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465528, encodeId=9f19146552821, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Oct 04 10:15:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139800, encodeId=f04c139800a7, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced11947358, createdName=猪猪霞, createdTime=Tue Oct 04 09:12:09 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2017-02-24 amy0559
  4. [GetPortalCommentsPageByObjectIdResponse(id=1929257, encodeId=730f192925e23, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jul 04 18:15:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050564, encodeId=bbcd2050564d2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 08 18:15:00 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671846, encodeId=02fd16e18467a, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri Feb 24 00:15:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696685, encodeId=280916966856c, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jun 01 22:15:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141127, encodeId=bce514112ebb, content=戒烟戒烟戒烟, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5Rzba0miciaDqB9IKh3iabPTt0b9S9puPOeouK5FKbP79ycicRtfibS0QUQzscofhYdIIBqEjojYTKIlnS3/0, createdBy=0f9c1961271, createdName=youyimu, createdTime=Thu Oct 06 17:10:06 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465528, encodeId=9f19146552821, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Oct 04 10:15:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139800, encodeId=f04c139800a7, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced11947358, createdName=猪猪霞, createdTime=Tue Oct 04 09:12:09 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2017-06-01 tomyang96
  5. [GetPortalCommentsPageByObjectIdResponse(id=1929257, encodeId=730f192925e23, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jul 04 18:15:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050564, encodeId=bbcd2050564d2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 08 18:15:00 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671846, encodeId=02fd16e18467a, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri Feb 24 00:15:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696685, encodeId=280916966856c, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jun 01 22:15:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141127, encodeId=bce514112ebb, content=戒烟戒烟戒烟, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5Rzba0miciaDqB9IKh3iabPTt0b9S9puPOeouK5FKbP79ycicRtfibS0QUQzscofhYdIIBqEjojYTKIlnS3/0, createdBy=0f9c1961271, createdName=youyimu, createdTime=Thu Oct 06 17:10:06 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465528, encodeId=9f19146552821, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Oct 04 10:15:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139800, encodeId=f04c139800a7, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced11947358, createdName=猪猪霞, createdTime=Tue Oct 04 09:12:09 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-06 youyimu

    戒烟戒烟戒烟

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1929257, encodeId=730f192925e23, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jul 04 18:15:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050564, encodeId=bbcd2050564d2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 08 18:15:00 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671846, encodeId=02fd16e18467a, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri Feb 24 00:15:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696685, encodeId=280916966856c, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jun 01 22:15:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141127, encodeId=bce514112ebb, content=戒烟戒烟戒烟, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5Rzba0miciaDqB9IKh3iabPTt0b9S9puPOeouK5FKbP79ycicRtfibS0QUQzscofhYdIIBqEjojYTKIlnS3/0, createdBy=0f9c1961271, createdName=youyimu, createdTime=Thu Oct 06 17:10:06 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465528, encodeId=9f19146552821, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Oct 04 10:15:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139800, encodeId=f04c139800a7, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced11947358, createdName=猪猪霞, createdTime=Tue Oct 04 09:12:09 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1929257, encodeId=730f192925e23, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Tue Jul 04 18:15:00 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050564, encodeId=bbcd2050564d2, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Feb 08 18:15:00 CST 2017, time=2017-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671846, encodeId=02fd16e18467a, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Fri Feb 24 00:15:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696685, encodeId=280916966856c, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jun 01 22:15:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141127, encodeId=bce514112ebb, content=戒烟戒烟戒烟, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5Rzba0miciaDqB9IKh3iabPTt0b9S9puPOeouK5FKbP79ycicRtfibS0QUQzscofhYdIIBqEjojYTKIlnS3/0, createdBy=0f9c1961271, createdName=youyimu, createdTime=Thu Oct 06 17:10:06 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465528, encodeId=9f19146552821, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Tue Oct 04 10:15:00 CST 2016, time=2016-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139800, encodeId=f04c139800a7, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced11947358, createdName=猪猪霞, createdTime=Tue Oct 04 09:12:09 CST 2016, time=2016-10-04, status=1, ipAttribution=)]
    2016-10-04 猪猪霞

    good

    0

相关资讯

革兰素史克计划提前向FDA提交COPD三药疗法上市申请

制药巨头葛兰素史克近日宣布,将向FDA提交一项慢性阻塞性肺病(COPD)三药联合鸡尾酒疗法的上市申请,比原计划提前了一年多。此前葛兰素史克计划在2018年之前提交这项申请,现在决定在2016年年底之前提交,并且同时向欧盟委员会提交上市申请。 这款日服一次的COPD鸡尾酒疗法是由葛兰素史克联合Innoviva(前身为Theravance)共同研发的,包含皮质类固醇氟替卡松糠酸盐、长效β受体激动

Lancet Respir Med:嗜酸性粒细胞计数预测COPD患者的肺炎风险

吸入糖皮质激素对慢性阻塞性肺疾病(COPD)的管理很重要,但是这种治疗方式会轻微增加中度至重度慢性阻塞性肺疾病患者的肺炎风险。血白细胞中嗜酸性粒细胞计数≥2% vs <2%,对吸入糖皮质激素反应更好;因此推测,血嗜酸性粒细胞计数也可能对COPD患者肺炎风险产生影响。本项事后荟萃分析,调查了使用2%的阈值,能否区分不同肺炎风险的患者,不管患者有没有吸入糖皮质激素治疗。 从GlaxoSmithK

Chiesi慢性阻塞性肺病三联疗法ICS/LABA/LAMA III期临床收获积极数据

意大利著名药企凯西制药集团(Chiesi)近日公布了慢性阻塞性肺病(COPD)三联疗法一项III期临床研究(TRILOGY)的积极数据。此次公布的为期一年期的数据证明,与标准的ICS/LABA组合疗法相比,其三联疗法ICS/LABA/LAMA在多个临床疗效参数方面均表现出统计学意义的显著卓越疗效。 该项研究中,年龄超过40岁确诊为重度或极重度COPD且最近发生至少一次急性发作(exacerbat

NEJM:茚达特罗–格隆溴铵治疗COPD比沙美特罗–氟替卡松更有效

大多数指南建议长效β受体激动剂(LABA)联合吸入糖皮质激素或长效毒蕈碱受体拮抗剂(LAMA)作为慢性阻塞性肺疾病(COPD)且具有高风险病情加重患者的首选治疗方法。LABA-LAMA治疗方案在这些患者中的作用尚不清楚。原始出处:Jadwiga A. Wedzicha,Donald Banerji,Kenneth R. Chapman,et al.Indacaterol–Glycopyrroniu

NEJM:糠酸氟替卡松–维兰特罗治疗可降低COPD恶化率

慢性阻塞性肺疾病(COPD)的管理证据来自密切监测的疗效试验,这些试验中的患者都是在限制招募条件的基础上被选择参与研究的。因此有必要在更接近常规临床实践条件下进行随机试验。

CHEST:COPD患者的持续性抑郁症状持续时间长,并加重病情

目前慢性阻塞性肺疾病(COPD)患者的抑郁症状长期轨迹及其影响的证据都还不够充分。在COPD纵向评估明确预测性替代终点研究中,研究人员分析了COPD患者的3年数据。在流行病学研究中心抑郁量表评分(<16 VS ≥16)和在基线抗抑郁药使用情况(是VS否)的基础上,患者被分为四组:从来没有抑郁症,新发,间歇性发作,和持续性抑郁症。通过使用逻辑回归分析方法,基线特征被用来评估该组相关的因素。共有

Baidu
map
Baidu
map
Baidu
map